血管内皮生长因子受体2抑制剂阿帕替尼抑制小鼠病理性眼新生血管
本研究在小鼠氧诱导视网膜病变(OIR)和激光诱导脉络膜新生血管(CNV)模型中,评估VEGFR2酪氨酸激酶抑制剂阿帕替尼的抗新生血管作用。阿帕替尼抑制VEGF介导的VEGFR2信号激活,减少HRMEC增殖、迁移和成管;单次玻璃体腔注射显著减轻OIR视网膜新生血管和激光诱导CNV,口服给药亦显著减少激光诱导CNV。
要点
- 阿帕替尼抑制VEGF介导的VEGFR2磷酸化及HRMEC增殖、迁移和成管。
- 单次玻璃体腔注射阿帕替尼显著减轻OIR视网膜和激光诱导CNV。
- 口服阿帕替尼显著减少激光诱导CNV,玻璃体腔注射未引起明显眼毒性。
核心结论
- 阿帕替尼抑制小鼠OIR和激光诱导CNV的病理性眼新生血管,可能成为缺血诱导的增殖性视网膜病变和新生血管性年龄相关性黄斑变性的有前景药物。
研究设计与样本
- 使用人视网膜微血管内皮细胞(HRMECs)进行Western blotting和体外血管生成实验。
- 新生小鼠从出生后第7天至第12天暴露于75%氧气,第12天至第17天暴露于室内空气以诱导OIR。
- 使用激光光凝在小鼠中诱导实验性CNV。
- 阿帕替尼通过玻璃体腔注射和口服给药,用免疫荧光染色评估新生血管和VEGFR2磷酸化。
主要发现
- 阿帕替尼抑制VEGF介导的VEGFR2信号激活,并大幅减少VEGF诱导的HRMECs增殖、迁移和成管。
- 单次玻璃体腔注射阿帕替尼显著减轻OIR小鼠的视网膜新生血管和激光损伤诱导CNV小鼠的脉络膜新生血管。
- 接受阿帕替尼治疗眼的视网膜或脉络膜组织中VEGFR2磷酸化水平大幅低于注射溶媒的对照眼。
- 玻璃体腔注射阿帕替尼未引起明显眼毒性。
- 口服阿帕替尼显著减少小鼠激光诱导CNV。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Vascular endothelial growth factor (VEGF) signaling via VEGF receptor 2 (VEGFR2) plays a crucial role in pathologic ocular neovascularization. In this study, we investigated the antiangiogenic effect of apatinib, a pharmacologic inhibitor of VEGFR2 tyrosine kinase, against oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (CNV) in mice. METHODS: Western blotting and in vitro angiogenesis assays were performed using human retinal microvascular endothelial cells (HRMECs). OIR was induced in neonatal mice by exposure to 75% oxygen from postnatal day (P) 7 to P12 and to room air from P12 to P17. Experimental CNV was induced in mice using laser photocoagulation. Apatinib was intravitreally and orally administered to mice. Neovascularization and phosphorylation of VEGFR2 were evaluated by immunofluorescence staining. RESULTS: Apatinib inhibited VEGF-mediated activation of VEGFR2 signaling and substantially reduced VEGF-induced proliferation, migration, and cord formation in HRMECs. A single intravitreal injection of apatinib significantly attenuated retinal or choroidal neovascularization in mice with OIR or laser injury-induced CNV, respectively. Retinal or choroidal tissues of the eyes treated with apatinib exhibited substantially lower phosphorylation of VEGFR2 than those of controls injected with vehicle. Intravitreal injection of apatinib did not cause noticeable ocular toxicity. Moreover, oral administration of apatinib significantly reduced laser-induced CNV in mice. CONCLUSIONS: Our study demonstrates that apatinib inhibits pathologic ocular neovascularization in mice with OIR or laser-induced CNV. Apatinib may, therefore, be a promising drug for the prevention and treatment of ischemia-induced proliferative retinopathy and neovascular age-related macular degeneration.
引用
- Kim KL, Suh W. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice. Invest Ophthalmol Vis Sci. 2017. PMID: 28715845. doi:10.1167/iovs.17-21416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。